Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis: Final Analysis From the DAYBREAK Open-label Extension Study

被引：0

作者：

Filippi, Massimo ^{[1
,2
]}

Henry, Roland ^{[3
]}

Arnold, Douglas ^{[4
,5
]}

Granziera, Cristina ^{[6
,7
,8
,9
,10
,11
,12
,13
,14
]}

Kappos, Ludwig ^{[9
,10
,11
,12
,13
,14
]}

Sheffield, James ^{[15
]}

Cheng, Chun-Yen ^{[15
]}

Riolo, Jon ^{[15
]}

Pachai, Chahin ^{[15
]}

Cree, Bruce A. C. ^{[3
]}

机构：

[1] IRCCS San Raffaele Sci Inst, Neurol Unit, Div Neurosci, Neuroimaging Res Unit,Neurorehabil Unit, Milan, Italy

[2] Univ Vita Salute San Raffaele, Neurophysiol Serv, Milan, Italy

[3] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA

[4] McGill Univ, NeuroRx Res, Montreal, PQ, Canada

[5] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[6] Univ Hosp Basel, Dept Biomed Engn, Translat Imaging Neurol ThINk Basel, Fac Med, Basel, Switzerland

[7] Univ Basel, Basel, Switzerland

[8] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[9] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[10] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[11] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[12] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[13] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[14] Univ Basel, Basel, Switzerland

[15] Bristol Myers Squibb, Princeton, NJ USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1451/510

引用

页码：922 / 923

页数：2

共 43 条

[31] Early Initiation of Ofatumumab Delays Disability Progression in People With Relapsing Multiple Sclerosis: 6-Year Results From ALITHIOS Open-Label Extension Study
Bar-Or, Amit
Hauser, Stephen L.
Cohen, Jeffrey A.
Montalban, Xavier
Bhatt, Alit
Wu, Min
Boer, Ibolya
Wiendl, Heinz
Kappos, Ludwig
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 167 - 168
[32] Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Gold, Ralf
Radue, Ernst-Wilhelm
Giovannoni, Gavin
Selmaj, Krzysztof
Havrdova, Eva Kubala
Montalban, Xavier
Stefoski, Dusan
Sprenger, Till
Robinson, Randy R.
Fam, Sami
Smith, Jonathan
Chalkias, Spyros
Giannattasio, Giorgio
Lima, Gabriel
Castro-Borrero, Wanda
JOURNAL OF NEUROLOGY, 2020, 267 (10) : 2851 - 2864
[33] MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
Colombel, Jean Frederic
Osterman, Mark T.
Ibanez, Patricio
Vermeire, Severine
Irving, Peter M.
Gardiner, Sean M.
Connelly, Susan B.
Mundayat, Rajiv
Lawendy, Nervin
Su, Chinyu
Reinisch, Walter
GASTROENTEROLOGY, 2021, 160 (06) : S125 - S126
[34] Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
Ford, C.
Goodman, A. D.
Johnson, K.
Kachuck, N.
Lindsey, J. W.
Lisak, R.
Luzzio, C.
Myers, L.
Panitch, H.
Preiningerova, J.
Pruitt, A.
Rose, J.
Rus, H.
Wolinsky, J.
MULTIPLE SCLEROSIS, 2010, 16 (03): : 342 - 350
[35] Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
Ford, Corey
Johnson, Kenneth
Kachuck, Norman
Lindsey, J. William
Lisak, Robert P.
Luzzio, Christopher
Myers, Lawrence
Panitch, Hillel
Preiningerova, Jane
Pruitt, Amy
Rose, John W.
Rus, Horea
Wolinsky, Jerry
MULTIPLE SCLEROSIS, 2008, 14 : S41 - S42
[36] Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
van der Heijde, Desiree
Wollenhaupt, Juergen
Cohen, Stanley B.
Strengholt, Sander
Terry, Ketti
DeMasi, Ryan
Kwok, Kenneth
Lazariciu, Irina
Wang, Lisy
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[37] Twenty Years of Continuous Treatment of Multiple Sclerosis with Glatiramer Acetate 20 mg/mL Daily: Long-Term Disability Outcomes in the US Open-Label Extension Study.
Kolodny, S.
Ford, C.
Grinspan, A.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 417 - 417
[38] Long-term efficacy and safety of ocrelizumab in treatment-naive patients with early relapsing multiple sclerosis: 7-year data from the OPERA open-label extension trials
Cerqueira, J.
Berthele, A.
Cree, B.
Filippi, M.
Pardo, G.
Pearson, O.
Trabloulsee, A.
Ziemssen, T.
Vollmer, T.
Bernasconi, C.
Mandel, C.
Overell, J.
Havrdova, E.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 634 - 635
[39] VISIONARY-MS Long-Term Extension Results: A Multi-Centre, Open-Label Long-Term Extension Study of CNM-Au8 in Patients with Stable Relapsing Multiple Sclerosis (RMS) on top of background disease modifying therapy (DMT)
Barnett, Michael
Beadnall, Heidi
Klistoner, Alexander
Sergott, Robert
Greenberg, Benjamin M.
Rynders, Austin
Ho, Karen
Sepassi, Marjan
Evan, Jacob
Evan, Jeremy
McBride, Ryan
Hartford, Alan
Hotchkin, Michael
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1209 - 1209
[40] Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
Rieckmann, Peter
Zivadinov, Robert
Boyko, Alexey
Selmaj, Krzysztof
Alexander, Jessica K.
Kadosh, Shaul
Rubinchick, Svetlana
Bernstein-Hanlon, Emily
Stark, Yafit
Ashtamker, Natalia
Davis, Mat D.
Khan, Omar
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)

← 1 2 3 4 5 →